Analysis of treatment response in metastatic prostate cancer using circulating tumour cells from longitudinal clinical trials and novel patient-derived organoids in culture
The aims of this project are:
-
Analyse longitudinal changes in CTCs from the ADMET trial of advanced metastatic prostate cancer patients initiating ADT and randomised to metformin. The CTCs will be expanded ex vivo in organoid culture to investigate intrapatient treatment response and response between treatment arms.
-
In a subset of ADMET patients from Aim 1, investigate the correlation, relevance and clinical utility of genomic analyses of patient matched CTCs, cfDNA and metastatic tissue biopsies as surrogate measures of metastatic disease, and treatment driven genomic selection.
Investigators
Duration
2016 - 2016
Funding
| PA Research Support Scheme | $75 000 |
